Marvin Johnson - 17 Apr 2023 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC.

Role
Director
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Apr 2023
Net transactions value
$0
Form type
4
Filing time
19 Apr 2023, 16:03:53 UTC
Previous filing
13 Jun 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNS Common Stock Award $0 +7,200 $0.000000 7,200 17 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNS Stock Option (Right to Buy) Award $0 +32,400 $0.000000 32,400 17 Apr 2023 Common Stock 32,400 $8.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). The RSUs will vest in three equal annual installments, with the first installment vesting on April 17, 2024, the second installment vesting on April 17, 2025 and the third installment vesting on April 17, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2 The option vests and becomes exercisable in 36 equal monthly installments beginning on May 17, 2023, subject to the reporting person's continued service with the Issuer.